But on Monday, Mylan said that the company actually has a pretax profit of $160 for the two-packs.
The post-tax profit totals $104, according to the company, which is under fire from consumers and Congress for having hiked the price EpiPens more than 500 percent in recent years. Its list price currently runs $608.
Bresch's testimony last week did not include the disclaimer that the profit she was stating was post-tax, not pretax.
Mylan told The Wall Street Journal on Monday that including the U.S. tax rate for the profits of products is "standard" and that Bresch did not intend to be unclear when asked about the profit rate.
In a statement to CNBC, Mylan said, "Tax is typically included in a standard profitability analysis and the information provided to Congress has made clear that tax was part of the EpiPen Auto-Injector profitability analysis."
"In fact, Mylan has provided Congress with a detailed analysis of EpiPen Auto-Injector profitability," said the company, which included a link to that analysis with its emailed comment. "It also is important to note that use of a statutory tax rate for the jurisdiction being analyzed (in this instance, the U.S.) is standard. Just as we did not use a blended global tax rate, we also did not allocate corporate expenses associated with running the business, which would have further reduced its profitability. We believe it is most appropriate, and conservative, to focus entirely on EpiPen Auto-Injector specific costs and associated taxes."
But Cummings wasn't impressed with Mylan's new math.
"We didn't believe Mylan's numbers last week during their CEO's testimony, and we don't believe them this week either, which is why we gave them 10 days from the date of our hearing to produce their internal files," Cummings said.
"They have until Friday to give Congress the underlying documents we asked for back in August so we can finally determine the company's actual profits in each year for the last decade," Cummings said.